Biohaven

and the 10-year U.S. Treasury yield finished at 4.95 percent.

The day's big stock move came from Biohaven.

Shares jumped more than 30 percent after the FDA agreed to review the company's submitted application for a drug for a rare inherited disorder that destroys balance and coordination.

The agency rejected the drug last November, and a decision is expected early next year.

Actually, our, our attorney-- We have a, an attorney that we use at Iaso that also is the same attorney at Bexorg, um, w- through Auric, and, and we got introduced initially, uh, that way.

Um, and then subsequently, after hearing about Bexorg, I was actually connected to a good friend of mine who was at, who's at Biohaven, leads their, uh, head of drug discovery over there, who mentioned that I really need to meet this company working on brains.

So this was kinda the second time I'd heard about this company working on brains.

Uh, you know, another big, exciting platform.

It was just-- I had such conviction, uh, in this platform.

I've deci-- I decided, uh, to join full-time.

And a couple of weeks ago, uh, alongside Bruce Carr, uh, who joined as our CSO, he came over from Biohaven.

I, I also joined as chief business officer.

From an approved drug to one still in testing.

Biohaven's BHV-1300, a Phase 3 candidate for Graves' disease.

Ono Pharmaceutical has agreed to license it for Japan and several other Asian markets before that Phase 3 has any results.

Graves is the most common cause of an overactive thyroid.

Drugs that cut hormone production, radioactive iodine, or surgery.

BHV1300 goes after the antibodies instead.

Biohaven describes it as lowering IgG antibodies broadly using the liver's own clearance.

That includes the thyroid-stimulating ones rather than singling them out.

Theramex's licensing of Asureze HPV cervical lesion treatment Cevira for Europe signifies a notable advance in women's health through innovative drug device combinations.

Meanwhile, Ono Pharmaceutical's licensing of Biohaven's Ig degraders for Asia-Pacific rights illustrates growing interest in protein degradation technologies within autoimmune disease spaces.

Promising clinical trial results have emerged from argenx's FB one hundred two, an anti-CD one hundred and twenty-two antibody that met its primary endpoint in a phase two trial for coeliac disease.

This monoclonal antibody targets the CD one hundred and twenty-two receptor and could offer hope to patients with this autoimmune condition.

Right

... pants, which, you know, were Biohaven's drug and a number of others, but AbbVie and, and Pfizer are doing incredibly well, and Lundbeck is doing really well with an IV product.

So in terms of revenue, inside of pharma, there's the scientific data.

There's the how do you get it approved, and how much does it cost to get there? And then it's h- what happens when you're commercially there? How do you compete? How do you rebate? How do you co- discount to get really cash to the bottom line to drive the business? So I think that there's aspects of this, you need to understand the history of what's going on in a market.

Why would I upgrade my plan? Not paying you guys enough.

I like Biohaven.

Good luck, Austin.

No, just be calm and confident.